| # | Drug | Count |
|---|---|---|
| 0 | CARBOPLATIN | 104 |
| 1 | PACLITAXEL | 82 |
| 2 | TRASTUZUMAB | 81 |
| 3 | PEMBROLIZUMAB | 79 |
| 4 | BEVACIZUMAB | 77 |
| 5 | CAPECITABINE | 77 |
| 6 | EVEROLIMUS | 74 |
| 7 | PACLITAXEL (AIBUMIN-BOUND) | 74 |
| 8 | NIVOLUMAB | 73 |
| 9 | LETROZOLE | 70 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | 4% LIDOCAINE | 1 | 0.0303 |
| 1 | MATICO, SARSAPARILLA (SMILAX REGELII), THUJA OCCIDENTALIS, UNCARIA TOMENTOSA, PHYLLANTHUS NIRURI, POLYGONUM CUSPIDATUM | 1 | 0.0139 |
| 2 | ISOTONIC SODIUM CHLORIDE | 1 | 0.0133 |
| 3 | ZONGERTINIB | 1 | 0.0060 |
| 4 | GEFITINIB | 43 | 0.0048 |
| 5 | AFATINIB | 27 | 0.0041 |
| 6 | DACOMITINIB | 3 | 0.0040 |
| 7 | VINORELBINE | 23 | 0.0033 |
| 8 | NALDEMEDINE | 5 | 0.0030 |
| 9 | BELZUTIFAN | 5 | 0.0028 |
| # | Drug class | Count |
|---|---|---|
| 0 | Kinase Inhibitor [EPC] | 275 |
| 1 | Platinum-based Drug [EPC] | 176 |
| 2 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 172 |
| 3 | Nucleoside Metabolic Inhibitor [EPC] | 128 |
| 4 | Microtubule Inhibitor [EPC] | 125 |
| 5 | Aromatase Inhibitor [EPC] | 110 |
| 6 | HER2/neu Receptor Antagonist [EPC] | 82 |
| 7 | Vascular Endothelial Growth Factor Inhibitor [EPC] | 81 |
| 8 | mTOR Inhibitor Immunosuppressant [EPC] | 76 |
| 9 | Corticosteroid [EPC] | 66 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 172 | 0.0017 |
| 1 | Bispecific gp100 Peptide-HLA-directed CD3 T Cell Engager [EPC] | 1 | 0.0017 |
| 2 | HER2/neu Receptor Antagonist [EPC] | 82 | 0.0011 |
| 3 | Aromatase Inhibitor [EPC] | 110 | 0.0010 |
| 4 | Estrogen Receptor Antagonist [EPC] | 39 | 0.0010 |
| 5 | Vascular Endothelial Growth Factor Receptor 2 Antagonist [EPC] | 6 | 0.0009 |
| 6 | Microtubule Inhibitor [EPC] | 125 | 0.0008 |
| 7 | Programmed Death Ligand-1 Blocker [EPC] | 14 | 0.0006 |
| 8 | Platinum-based Drug [EPC] | 176 | 0.0006 |
| 9 | Calcitonin [EPC] | 2 | 0.0006 |